{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:57:54Z","timestamp":1792936674776,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1038\/tpj.2015.53","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T10:00:42Z","timestamp":1437472842000},"page":"336-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Paradoxical psoriasiform reactions to anti-TNF\u03b1 drugs are associated with genetic polymorphisms in patients with psoriasis"],"prefix":"10.1038","volume":"16","author":[{"given":"T","family":"Cabaleiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Prieto-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Solano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Abad-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,21]]},"reference":[{"key":"BFtpj201553_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM . Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377\u2013385.","journal-title":"J Invest Dermatol"},{"key":"BFtpj201553_CR2","first-page":"231","volume":"80","author":"GA Severs","year":"2007","unstructured":"Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R . Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis 2007; 80: 231\u2013237.","journal-title":"Cutis"},{"key":"BFtpj201553_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000107622","volume":"215","author":"B Passarini","year":"2007","unstructured":"Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology 2007; 215: 295\u2013300.","journal-title":"Dermatology"},{"key":"BFtpj201553_CR4","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/art.23835","volume":"59","author":"AN Collamer","year":"2008","unstructured":"Collamer AN, Guerrero KT, Henning JS, Battafarano DF . Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 2008; 59: 996\u20131001.","journal-title":"Arthritis Rheum."},{"key":"BFtpj201553_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/1153420-S0-000000000-00000","volume":"11","author":"F Rongioletti","year":"2010","unstructured":"Rongioletti F, Burlando M, Parodi A . Adverse effects of biological agents in the treatment of psoriasis. Am J Clin Dermatol 2010; 11: 35\u201337.","journal-title":"Am J Clin Dermatol"},{"key":"BFtpj201553_CR6","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1007\/s00296-011-2265-4","volume":"32","author":"A L\u00f3pez-Robles","year":"2012","unstructured":"L\u00f3pez-Robles A, Queiro R, Alperi M, Alonso S, Riestra JL, Ballina J . Psoriasis and psoriasiform lesions induced by TNF\u03b1 antagonists: the experience of a tertiary care hospital from northern Spain. Rheumatol Int 2012; 32: 3779\u20133783.","journal-title":"Rheumatol Int"},{"key":"BFtpj201553_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","volume":"7","author":"R Denadai","year":"2013","unstructured":"Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R . Induction or exacerbation of psoriatic lesions during anti-TNF-\u03b1 therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis 2013; 7: 517\u2013524.","journal-title":"J Crohns Colitis"},{"key":"BFtpj201553_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ad.2013.05.007","volume":"105","author":"R Navarro","year":"2014","unstructured":"Navarro R, Daud\u00e9n E . Clinical management of paradoxical psoriasiform reactions during TNF-\u03b1 therapy. Actas Dermosifiliogr 2014; 105: 752\u2013761.","journal-title":"Actas Dermosifiliogr"},{"key":"BFtpj201553_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"U Wollina","year":"2008","unstructured":"Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G . Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1\u201314.","journal-title":"Am J Clin Dermatol"},{"key":"BFtpj201553_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/09546630802441234","volume":"20","author":"JM Ko","year":"2009","unstructured":"Ko JM, Gottlieb AB, Kerbleski JF . Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009; 20: 100\u2013108.","journal-title":"J Dermatolog Treat"},{"key":"BFtpj201553_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","volume":"40","author":"AN Collamer","year":"2010","unstructured":"Collamer AN, Battafarano DF . Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40: 233\u2013240.","journal-title":"Semin Arthritis Rheum"},{"key":"BFtpj201553_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","volume":"34","author":"G Cullen","year":"2011","unstructured":"Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR . Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34: 1318\u20131327.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFtpj201553_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1345\/aph.1C477","volume":"38","author":"MM Verea","year":"2004","unstructured":"Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E . Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38: 54\u201357.","journal-title":"Ann Pharmacother"},{"key":"BFtpj201553_CR14","first-page":"1411","volume":"33","author":"I Sari","year":"2006","unstructured":"Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N . Anti-tumor necrosis factor-alpha-induced psoriasis. J Rheumatol 2006; 33: 1411\u20131414.","journal-title":"J Rheumatol"},{"key":"BFtpj201553_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2230.2006.02315.x","volume":"32","author":"R Goiriz","year":"2007","unstructured":"Goiriz R, Dauden E, Perez-Gala S, Guhl G, Garcia-Diez A . Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol 2007; 32: 176\u2013179.","journal-title":"Clin Exp Dermatol"},{"key":"BFtpj201553_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nrgastro.2010.7","volume":"7","author":"LS Conklin","year":"2010","unstructured":"Conklin LS, Cohen B, Wilson L, Cuffari C, Oliva-Hemker M . Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. Nat Rev Gastroenterol Hepatol 2010; 7: 174\u2013147.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"BFtpj201553_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/039463201202500220","volume":"25","author":"A Tammaro","year":"2012","unstructured":"Tammaro A, Persechino S, Abruzzese C, Narcisi A, Cortesi G, Parisella FR et al. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab. Int J Immunopathol Pharmacol 2012; 25: 499\u2013501.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"BFtpj201553_CR18","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A . Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005; 52: 2513\u20132518.","journal-title":"Arthritis Rheum"},{"key":"BFtpj201553_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1586\/1744666X.2014.866038","volume":"10","author":"D Wendling","year":"2014","unstructured":"Wendling D, Prati C . Paradoxical effects of anti-TNF-\u03b1 agents in inflammatory diseases. Expert Rev Clin Immunol 2014; 10: 159\u2013169.","journal-title":"Expert Rev Clin Immunol"},{"key":"BFtpj201553_CR20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","volume":"161","author":"J Seneschal","year":"2009","unstructured":"Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Ta\u00efeb A . Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009; 161: 1081\u20131088.","journal-title":"Br J Dermatol"},{"key":"BFtpj201553_CR21","doi-asserted-by":"publisher","first-page":"e69827","DOI":"10.1371\/journal.pone.0069827","volume":"8","author":"ME Ariza","year":"2013","unstructured":"Ariza ME, Rivailler P, Glaser R, Chen M, Williams MV . Epstein-Barr virus encoded dUTPase containing exosomes modulate innate and adaptive immune responses in human dendritic cells and peripheral blood mononuclear cells. PLoS One 2013; 8: e69827.","journal-title":"PLoS One"},{"key":"BFtpj201553_CR22","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/bjd.13585","volume":"172","author":"R Prieto-P\u00e9rez","year":"2015","unstructured":"Prieto-P\u00e9rez R, Solano-L\u00f3pez G, Cabaleiro T, Rom\u00e1n M, Ochoa D, Taleg\u00f3n M et al. New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: a case-control study. Br J Dermatol. 2015; 172: 1432\u20131435.","journal-title":"Br J Dermatol."},{"key":"BFtpj201553_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/MPG.0b013e31828390ba","volume":"56","author":"ME Sherlock","year":"2013","unstructured":"Sherlock ME, Walters T, Tabbers MM, Frost K, Zachos M, Muise A et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr 2013; 56: 512\u2013518.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"BFtpj201553_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1\u201310.","journal-title":"Arch Dermatol Res"},{"key":"BFtpj201553_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/tpj.2012.53","volume":"13","author":"R Prieto-P\u00e9rez","year":"2013","unstructured":"Prieto-P\u00e9rez R, Cabaleiro T, Dauden E, Abad-Santos F . Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 2013; 13: 297\u2013305.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201553_CR26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1684\/ejd.2013.2144","volume":"23","author":"T Cabaleiro","year":"2013","unstructured":"Cabaleiro T, Roman M, Gallo E, Ochoa D, Tudelilla F, Taleg\u00f3n M et al. Association between psoriasis and polymorphisms in the TNF, IL12B, and IL23R genes in Spanish patients. Eur J Dermatol 2013; 23: 640\u2013645.","journal-title":"Eur J Dermatol"},{"key":"BFtpj201553_CR27","first-page":"380","volume":"34","author":"JD Cohen","year":"2007","unstructured":"Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007; 34: 380\u2013385.","journal-title":"J Rheumatol"},{"key":"BFtpj201553_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ard.2007.087288","volume":"68","author":"MJ Harrison","year":"2009","unstructured":"Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009; 68: 209\u2013215.","journal-title":"Ann Rheum Dis"},{"key":"BFtpj201553_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/RHU.0b013e3182a702e8","volume":"19","author":"K Nguyen","year":"2013","unstructured":"Nguyen K, Vleugels RA, Velez NF, Merola JF, Qureshi AA . Psoriasiform reactions to anti-tumor necrosis factor \u03b1 therapy. J Clin Rheumatol 2013; 19: 377\u2013381.","journal-title":"J Clin Rheumatol"},{"key":"BFtpj201553_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","volume":"8","author":"A Afzali","year":"2014","unstructured":"Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD . The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis 2014; 8: 480\u2013488.","journal-title":"J Crohns Colitis"},{"key":"BFtpj201553_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","volume":"63","author":"C Tillack","year":"2014","unstructured":"Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment. Gut 2014; 63: 567\u2013577.","journal-title":"Gut"},{"key":"BFtpj201553_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000358288","volume":"89","author":"C Barthel","year":"2014","unstructured":"Barthel C, Biedermann L, Frei P, Vavricka SR, K\u00fcndig T, Fried M et al. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies. Digestion 2014; 89: 209\u2013215.","journal-title":"Digestion"},{"key":"BFtpj201553_CR33","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1155\/2009\/514618","volume":"23","author":"M Shale","year":"2009","unstructured":"Shale M, Ghosh S . Learning the lessons of antitumour necrosis factor therapy-associated psoriasis. Can J Gastroenterol 2009; 23: 674\u2013676.","journal-title":"Can J Gastroenterol"},{"key":"BFtpj201553_CR34","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.3748\/wjg.v20.i22.7019","volume":"20","author":"M W\u0142odarczyk","year":"2014","unstructured":"W\u0142odarczyk M, Sobolewska A, W\u00f3jcik B, Loga K, Fichna J, Wi\u015bniewska-Jarosi\u0144ska M . Correlations between skin lesions induced by anti-tumor necrosis factor-\u03b1 and selected cytokines in Crohn's disease patients. World J Gastroenterol 2014; 20: 7019\u20137026.","journal-title":"World J Gastroenterol"},{"key":"BFtpj201553_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/pmj.76.896.365","volume":"76","author":"C Taylor","year":"2000","unstructured":"Taylor C, Burns D, Wiselka M . Extensive psoriasis induced by interferon alpha treatment for chronic hepatitis C. Postgrad Med J 2000; 76: 365\u2013367.","journal-title":"Postgrad Med J"},{"key":"BFtpj201553_CR36","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/j.0022-202X.2005.23864.x","volume":"125","author":"KW Eriksen","year":"2005","unstructured":"Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C et al. Increased sensitivity to interferonalpha in psoriatic T cells. J Invest Dermatol 2005; 125: 936\u2013944.","journal-title":"J Invest Dermatol"},{"key":"BFtpj201553_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1084\/jem.20050500","volume":"202","author":"FO Nestle","year":"2005","unstructured":"Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135\u2013143.","journal-title":"J Exp Med"},{"key":"BFtpj201553_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J . Psorasis. N Engl J Med 2009; 361: 496\u2013509.","journal-title":"N Engl J Med"},{"key":"BFtpj201553_CR39","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semarthrit.2007.05.004","volume":"37","author":"B Grinblat","year":"2008","unstructured":"Grinblat B, Scheinberg M . The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008; 37: 251\u2013255.","journal-title":"Semin Arthritis Rheum"},{"key":"BFtpj201553_CR40","doi-asserted-by":"publisher","first-page":"e17160","DOI":"10.1371\/journal.pone.0017160","volume":"6","author":"P Di Meglio","year":"2011","unstructured":"Di Meglio P, Di Cesare A, Laggner U, Chu CC, Napolitano L, Villanova F et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS ONE 2011; 6: e17160.","journal-title":"PLoS ONE"},{"key":"BFtpj201553_CR41","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ng.693","volume":"42","author":"PE Stuart","year":"2010","unstructured":"Stuart PE, Nair RP, Ellinghaus E, Ding J, Tejasvi T, Gudjonsson JE et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010; 42: 1000\u20131004.","journal-title":"Nat Genet"},{"key":"BFtpj201553_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3899\/jrheum.111242","volume":"39","author":"P Rahman","year":"2012","unstructured":"Rahman P, Elder JT . Genetics of psoriasis and psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012; 39: 431\u2013433.","journal-title":"J Rheumatol"},{"key":"BFtpj201553_CR43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/ni.2341","volume":"13","author":"J Zhao","year":"2012","unstructured":"Zhao J, Wei J, Mialki RK, Mallampalli DF, Chen BB, Coon T et al. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat Immunol 2012; 13: 651\u2013658.","journal-title":"Nat Immunol"},{"key":"BFtpj201553_CR44","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/j.bbamcr.2013.07.005","volume":"1833","author":"J Wei","year":"2013","unstructured":"Wei J, Mialki RK, Dong S, Khoo A, Mallampalli RK, Zhao Y et al. A new mechanism of RhoA ubiquitination and degradation: roles of SCF(FBXL19) E3 ligase and Erk2. Biochim Biophys Acta 2013; 1833: 2757\u20132764.","journal-title":"Biochim Biophys Acta"},{"key":"BFtpj201553_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1089\/dna.2010.1021","volume":"29","author":"K Repnik","year":"2010","unstructured":"Repnik K, Potocnik U . CTLA4 CT60 single-nucleotide polymorphism is associated with Slovenian inflammatory bowel disease patients and regulates expression of CTLA4 isoforms. DNA Cell Biol 2010; 29: 603\u2013610.","journal-title":"DNA Cell Biol"},{"key":"BFtpj201553_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1101\/sqb.1999.64.303","volume":"64","author":"CA Chambers","year":"1999","unstructured":"Chambers CA, Allison JP . CTLA-4\u2014the costimulatory molecule that doesn\u2019t: regulation of T-cell responses by inhibition. Cold Spring Harb Symp Quant Biol 1999; 64: 303\u2013312.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"BFtpj201553_CR47","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.4049\/jimmunol.177.7.4376","volume":"177","author":"S Read","year":"2006","unstructured":"Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006; 177: 4376\u20134383.","journal-title":"J Immunol"},{"key":"BFtpj201553_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1034\/j.1600-065X.2001.1820102.x","volume":"182","author":"S Sakaguchi","year":"2001","unstructured":"Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M et al. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev 2001; 182: 18\u201332.","journal-title":"Immunol. Rev"},{"key":"BFtpj201553_CR49","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.4103\/0976-500X.120943","volume":"4","author":"F Ursini","year":"2013","unstructured":"Ursini F, Naty S, Russo E, Grembiale RD . Abatacept in psoriatic arthritis: case report and short review. J Pharmacol Pharmacother 2013; 4: S29\u2013S32.","journal-title":"J Pharmacol Pharmacother"},{"key":"BFtpj201553_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1006\/geno.2002.6720","volume":"79","author":"D Hewett","year":"2002","unstructured":"Hewett D, Samuelsson L, Polding J, Enlund F, Smart D, Cantone K et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 2002; 79: 305\u2013314.","journal-title":"Genomics"},{"key":"BFtpj201553_CR51","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/ijd.12213","volume":"52","author":"A Vasku","year":"2013","unstructured":"Vasku A, Bienertova-Vasku J, Izakovicova-Holla L, Pavkova Goldbergova M, Kozacikova Z, Splichal Z et al. Polymorphisms in HLA-related genes and psoriasis heredity in patients with psoriasis. Int J Dermatol 2013; 52: 960\u2013965.","journal-title":"Int J Dermatol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201553","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T11:12:13Z","timestamp":1647947533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,21]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["BFtpj201553"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2015.53","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,21]]},"assertion":[{"value":"11 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E Daud\u00e9n has conflict of interest (advisory board member, consultant, grants, research support, participation in clinical trials, honoraria for speaking and research support) with the following pharmaceutical companies: AbbVie (Abbott), Amgen, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD and Celgene. F Abad-Santos and D Ochoa have been consultants or investigators in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Faes, Farmal\u00edder, Ferrer, GlaxoSmithKline, Janssen-Cilag, Kern, Normon, Servier, Teva and Zambon. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}